news roundup
CluePoints, a provider of RBM and Data Quality Oversight solutions, announces four year partnership with ONO Pharmaceutical. This agreement will see that ONO utilizes CluePoints centralized statistical monitoring platform in order to drive its RBM strategy and position in Japan.
| Advertisement
Debunking the Myths of Risk-Based Monitoring for a New Approach to Quality Management
On Demand
 Learn More |
Synteract, a CRO providing full-service Phase I-IV clinical trials, has acquired Cu-Tech, a dermatology specialist CRO. With this acquirement, Synteract has created a dedicated center of dermatology development.
| Advertisement
Predicting Holistic Clinical Trial Cost Should Not Be A Struggle
Ying Jiang Explains What You Need To Know
On Demand
 Learn more |
Clinerion has signed a Memorandum of Understanding with the P-HIS Development Group of Korea University Medical Center to support activities in developing a patient data platform in the Republic of Korea for precision medicine.
Peter O'Donnell explores the convergence of policy and science in new vaccine R&D pursuits in Europe.
|
|
|
| Advertisement
FILLING THE GAPS IN SITE SELECTION
What You Don't Know Can Help You
On Demand
 Learn more |
| Advertisement
Driving Product Development and Finding the Fast Track in Early-Phase Oncology Programs
On Demand
 Learn more |
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers » |
|
|
|
Articles
Companies can utilize the following five tools to set themselves up for a successful trial.
The Office for Human Research Protections at the US Department of Health and Human Services and the US Food and Drug Administration issued a final guidance on May 17 on Institutional Review Board written procedures, which are required under both OHRP and FDA regulations.
|
|
Blog Posts
Given the rapid changes in the communication landscape brought about by participative Internet use and social media, it is important to develop a better understanding of these technologies and their impact on health communication.
Patients stand to lose the most when sponsors hold too tightly to drugs doomed to fail. This wastes precious time that patients don't have and squanders valuable resources.
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription |
|
|
|
|
|
